Pfizer’s oral covid drug approved in China
Kathmandu, February 12. China has given conditional approval for Pfizer’s oral covid drug, Paxlovid. It is approved for treatment of mild to moderate adult patients of covid, with high risk of devloping a severe disease.
National Medical Products Administration (NMPA), China’s top medical regulator revealed in a statement that although the drug has been approved, more research needs to be done. The oral drug can be used by patients who have underlying problems like chronic kidney disease, diabetes, cardiovascular disease and chronic lung disease.
With vaccination being the key measure to fight against the disease, China has been able to fully vaccinate majority of its population.
China has adopted the “dynamic zero case” strategy to contain the spread of COVID-19. The early four measures for prevention-early detection, early reporting, early quarantine, and early treatment is being adopted.
Facebook Comment
Related News
latest Video
Trending News
- This Week
- This Month
